GlassScriptPhysician profile
Amanda A Wehner
NPI 1356709919
$3,010.05
in general payments reported to CMS, 2019-2025
26 companies · $1,362 in 2025
The $1,362 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $173 · 2022: $99.38 · 2023: $584 · 2024: $792 · 2025: $1,362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,094 · Education: $644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,093.78 |
| Education | $643.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $403.30 | 2024-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $352.14 | 2023-2025 | Reblozyl, Pomalyst, Opdivo |
| Astrazeneca Pharmaceuticals LP | $221.76 | 2023-2025 | Imfinzi, Calquence |
| Astellas Pharma US INC | $215.76 | 2021-2025 | Xtandi, Vyloy |
| Pfizer INC. | $192.35 | 2023-2025 | |
| Seagen INC. | $183.99 | 2025 | |
| Merck Sharp & Dohme LLC | $169.89 | 2023-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Incyte Corporation | $156.21 | 2025 | Jakafi, Monjuvi, Zynyz |
| Novartis Pharmaceuticals Corporation | $146.61 | 2024-2025 | |
| Eisai INC. | $111.14 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $105.40 | 2023 | |
| Karyopharm Therapeutics INC. | $99.38 | 2022 | |
| Tempus Ai, INC | $99.35 | 2025 | Xt Cdx |
| Glaxosmithkline, LLC. | $86.94 | 2023-2025 | Jemperli, Zejula, Ojjaara |
| Janssen Biotech, INC. | $77.58 | 2025 | Rybrevant, Darzalex, Tecvayli |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $63.10 | 2023-2025 | Itovebi, Tecentriq, Kadcyla |
| Solventum Corporation | $56.22 | 2024 | Activ.A.C. |
| Beone Medicines USA, INC. | $53.51 | 2025 | Brukinsa |
| Celgene Corporation | $52.25 | 2023 | Reblozyl, Opdualag |
| Array Biopharma INC | $35.07 | 2025 | Lorbrena, Mektovi, Braftovi |
| Abbvie INC. | $33.38 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $23.04 | 2025 | Exparel, Zilretta |
| Pharmacosmos Therapeutics INC. | $19.64 | 2025 | Monoferric |
| Takeda Pharmaceuticals U.S.A., INC. | $19.15 | 2025 | Iclusig |
| Amgen INC. | $16.77 | 2025 | Prolia, Evenity |
| Syndax Pharmaceuticals, INC. | $16.12 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Wehner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.